Cara Therapeutics Inc at Bank of America Merrill Lynch Healthcare Conference (Virtual) Transcript
Good day, everybody. My name is Jason Gerberry. I -- well, first off, I want to thank everybody for joining us for day 3 of the Bank of America Virtual Healthcare Conference. I'm the SMID cap, biotech and specialty pharma analyst at Bank of America, and I'm pleased to be introducing our next company presenter, Cara Therapeutics and CEO, Derek Chalmers. For those on the line, Cara is developing therapeutics for pruritus or itch that tends to be more moderate to severe in nature. The company recently reported positive Phase III data from its second confirmatory trial for KALM-2 for end-stage renal disease, patients who are suffering from itch, and the company is also exploring applications of this small AD in an oral formulation. And so we'll be looking to talk upon each of these topics today with Derek.
So first off, Derek, thanks so much for joining us.
Good morning, Jason.
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
